Counteraction of the multifunctional restriction factor tetherin

Frontiers in Microbiology

Volumn 5, Issue APR, 2014, Pages

  Sauter, Daniel ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

BST 2; HIV; ISG; Moonlighting proteins; Nef; Restriction factor; Tetherin; Vpu

Indexed keywords

CD82 ANTIGEN; ENVELOPE PROTEIN; GLYCOPROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON STIMULATED GENE FACTOR 3; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MEMBRANE PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; STAT3 PROTEIN; TETHERIN; TRIPARTITE MOTIF PROTEIN 5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGENEIC RESTRICTION; ANTIVIRAL ACTIVITY; ARTICLE; ELECTRON MICROSCOPY; ENDOCYTOSIS; GENE EXPRESSION; GOLGI COMPLEX; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RNA EDITING; RNA SPLICING; SEQUENCE HOMOLOGY; TRANS GOLGI NETWORK; UBIQUITINATION; VIRUS INHIBITION; VIRUS RELEASE; VIRUS REPLICATION;

EID: 84899670501     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00163     Document Type: Article

References (173)

1. Agromayor M. Soler N. Caballe A. Kueck T. Freund S. M. Allen M. D. et al. (2012). The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a SOUBA domain. Structure 20 414-428. doi: 10.1016/j.str.2011.12.013
2. Aldrovandi G. M. and Zack J. A. (1996). Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J. Virol. 70 1505-1511.
3. Alvarez R. A. Hamlin R. E. Monroe A. Moldt B. Hotta M. T. Rodriguez Caprio G. et al. (2014). HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J. Virol. doi: 10.1128/JVI.00449-14 [Epub ahead of print].
4. Amet T. Byrd D. Hu N. Sun Q. Li F. Zhao Y. et al. (2014). BST-2 expression in human hepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus. Curr. Mol. Med. 14 349-360. doi: 10.2174/1566524013666131118111719
5. Andrew A. J. Miyagi E. and Strebel K. (2011). Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J. Virol. 85 2611-2619. doi: 10.1128/JVI.02080-10
6. Arnaud F. Black S. G. Murphy L. Griffiths D. J. Neil S. J. Spencer T. E. et al. (2010). Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses. J. Virol. 84 4415-4425. doi: 10.1128/JVI.00029-10
7. Ayouba A. Akoua-Koffi C. Calvignac-Spencer S. Esteban A. Locatelli S. Li H. et al. (2013). Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Côte d'Ivoire. AIDS Lond. Engl. 27 2488-2491. doi: 10.1097/01.aids.0000432443.22684.50
8. Ayouba A. Souquières S. Njinku B. Martin P. M. Müller-Trutwin M. C. Roques P. et al. (2000). HIV-1 group N among HIV-1-seropositive individuals in Cameroon. AIDS Lond. Engl. 14 2623-2625. doi: 10.1097/00002030-200011100-00033
9. Bampi C. Rasga L. and Roux L. (2013). Antagonism to human BST-2/tetherin by Sendai virus glycoproteins. J. Gen. Virol. 94 1211-1219. doi: 10.1099/vir.0.051771-0
10. Barrett B. S. Smith D. S. Li S. X. Guo K. Hasenkrug K. J. and Santiago M. L. (2012). A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog. 8:e1002596. doi: 10.1371/journal.ppat.1002596
11. Bartee E. McCormack A. and Früh K. (2006). Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2:e107. doi: 10.1371/journal.ppat.0020107
12. Bego M. G. Mercier J. and Cohen E. A. (2012). Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J. Virol. 86 3513-3527. doi: 10.1128/JVI.06971-11
13. Bhattacharya J. Repik A. and Clapham P. R. (2006). Gag regulates association of human immunodeficiency virus type 1 envelope with detergent-resistant membranes. J. Virol. 80 5292-5300. doi: 10.1128/JVI.01469-05
14. Billcliff P. G. Gorleku O. A. Chamberlain L. H. and Banting G. (2013). The cytosolic N-terminus of CD317/tetherin is a membrane microdomain exclusion motif. Biol. Open 2 1253-1263. doi: 10.1242/bio.20135793
15. Blasius A. L. Giurisato E. Cella M. Schreiber R. D. Shaw A. S. and Colonna M. (2006). Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 177 3260-3265.
16. Blondeau C. Pelchen-Matthews A. Mlcochova P. Marsh M. Milne R. S. B. and Towers G. J. (2013). Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M. J. Virol. 87 13124-13133. doi: 10.1128/JVI.02250-13
17. Cai D. Cao J. Li Z. Zheng X. Yao Y. Li W. et al. (2009). Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 9:102. doi: 10.1186/1471-2407-9-102
18. Cao W. Bover L. Cho M. Wen X. Hanabuchi S. Bao M. et al. (2009). Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 206 1603-1614. doi: 10.1084/jem.20090547
19. Cao W. Rosen D. B. Ito T. Bover L. Bao M. Watanabe G. et al. (2006). Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J. Exp. Med. 203 1399-1405. doi: 10.1084/jem.20052454
20. Capurso G. Lattimore S. Crnogorac-Jurcevic T. Panzuto F. Milione M. Bhakta V. et al. (2006). Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer 13 541-558. doi: 10.1677/erc.1.01153
21. Casartelli N. Sourisseau M. Feldmann J. Guivel-Benhassine F. Mallet A. Marcelin A.-G. et al. (2010). Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog. 6:e1000955. doi: 10.1371/journal.ppat.1000955
22. Celestino M. Calistri A. Del Vecchio C. Salata C. Chiuppesi F. Pistello M. et al. (2012). Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein. J. Virol. 86 6688-6700. doi: 10.1128/JVI.07037-11
23. Cho M. Ishida K. Chen J. Ohkawa J. Chen W. Namiki S. et al. (2008). SAGE library screening reveals ILT7 as a specific plasmacytoid dendritic cell marker that regulates type I IFN production. Int. Immunol. 20 155-164. doi: 10.1093/intimm/dxm127
24. Coadou G. Evrard-Todeschi N. Gharbi-Benarous J. Benarous R. and Girault J. P. (2002). HIV-1 encoded virus protein U (Vpu) solution structure of the 41-62 hydrophilic region containing the phosphorylated sites Ser52 and Ser56. Int. J. Biol. Macromol. 30 23-40. doi: 10.1016/S0141-8130(01)00184-2
25. Coadou G. Gharbi-Benarous J. Megy S. Bertho G. Evrard-Todeschi N. Segeral E. et al. (2003). NMR studies of the phosphorylation motif of the HIV-1 protein Vpu bound to the F-box protein beta-TrCP. Biochemistry 42 14741-14751. doi: 10.1021/bi035207u
26. Cobos Jiménez V. Booiman T. de Taeye S. W. van Dort K. A. Rits M. A. N. Hamann J. et al. (2012). Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Sci. Rep. 2 763. doi: 10.1038/srep00763
27. Cocka L. J. and Bates P. (2012). Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog. 8:e1002931. doi: 10.1371/journal.ppat.1002931
28. Cole G. Simonetti K. Ademi I. and Sharpe S. (2012). Dimerization of the transmembrane domain of human tetherin in membrane mimetic environments. Biochemistry 51 5033-5040. doi: 10.1021/bi201747t
29. Dafa-Berger A. Kuzmina A. Fassler M. Yitzhak-Asraf H. Shemer-Avni Y. and Taube R. (2012). Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology 428 98-111. doi: 10.1016/j.virol.2012.03.011
30. Dave V. P. Hajjar F. Dieng M. M. Haddad É. and Cohen É. A. (2013). Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. Retrovirology 10 128. doi: 10.1186/1742-4690-10-128
31. Delaguillaumie A. Harriague J. Kohanna S. Bismuth G. Rubinstein E. Seigneuret M. et al. (2004). Tetraspanin CD82 controls the association of cholesterol-dependent microdomains with the actin cytoskeleton in T lymphocytes: relevance to co-stimulation. J. Cell Sci. 117 5269-5282. doi: 10.1242/jcs.01380
32. Delaugerre C. De Oliveira F. Lascoux-Combe C. Plantier J.-C. and Simon F. (2011). HIV-1 group N: travelling beyond Cameroon. Lancet 378 1894. doi: 10.1016/S0140-6736(11)61457-8
33. de Veer M. J. Holko M. Frevel M. Walker E. Der S. Paranjape J. M. et al. (2001). Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69 912-920.
34. Dietrich I. McMonagle E. L. Petit S. J. Vijayakrishnan S. Logan N. Chan C. N. et al. (2011). Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J. Virol. 85 5840-5852. doi: 10.1128/JVI.00071-11
35. Douglas J. L. Viswanathan K. McCarroll M. N. Gustin J. K. Früh K. and Moses A. V. (2009). Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J. Virol. 83 7931-7947. doi: 10.1128/JVI.00242-09
36. Dubé M. Roy B. B. Guiot-Guillain P. Mercier J. Binette J. Leung G. et al. (2009). Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 83 4574-4590. doi: 10.1128/JVI.01800-08
37. Erikson E. Adam T. Schmidt S. Lehmann-Koch J. Over B. Goffinet C. et al. (2011). In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc. Natl. Acad. Sci. U.S.A. 108 13688-13693. doi: 10.1073/pnas.1101684108
38. Fernandez-Suarez X. M. Rigden D. J. and Galperin M. Y. (2013). The 2014 nucleic acids research database issue and an updated NAR online molecular biology database collection. Nucleic Acids Res. 42 D1-D6. doi: 10.1093/nar/gkt1282
39. Frost A. Unger V. M. and De Camilli P. (2009). The BAR domain superfamily: membrane-molding macromolecules. Cell 137 191-196. doi: 10.1016/j.cell.2009.04.010
40. Galão R. P. Le Tortorec A. Pickering S. Kueck T. and Neil S. J. D. (2012). Innate sensing of HIV-1 assembly by Tetherin induces NFkB-dependent proinflammatory responses. Cell Host Microbe 12 633-644. doi: 10.1016/j.chom.2012.10.007
41. Garcia J. V. and Miller A. D. (1991). Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350 508-511. doi: 10.1038/350508a0
42. Ge Y. Dombkowski A. A. LaFiura K. M. Tatman D. Yedidi R. S. Stout M. L. et al. (2006). Differential gene expression GATA1 target genes and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107 1570-1581. doi: 10.1182/blood-2005-06-2219
43. Goffinet C. Allespach I. Homann S. Tervo H.-M. Habermann A. Rupp D. et al. (2009). HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5 285-297. doi: 10.1016/j.chom.2009.01.009
44. Goffinet C. Homann S. Ambiel I. Tibroni N. Rupp D. Keppler O. T. et al. (2010a). Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J. Virol. 84 4089-4094. doi: 10.1128/JVI.01549-09
45. Goffinet C. Schmidt S. Kern C. Oberbremer L. and Keppler O. T. (2010b). Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J. Virol. 84 11374-11384. doi: 10.1128/JVI.01067-10
46. Goto T. Kennel S. J. Abe M. Takishita M. Kosaka M. Solomon A. et al. (1994). A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84 1922-1930.
47. Götz N. Sauter D. Usmani S. M. Fritz J. V. Goffinet C. Heigele A. et al. (2012). Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 12 373-380. doi: 10.1016/j.chom.2012.07.008
48. Groom H. C. T. Yap M. W. Galão R. P. Neil S. J. D. and Bishop K. N. (2010). Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc. Natl. Acad. Sci. U.S.A. 107 5166-5171. doi: 10.1073/pnas.0913650107
49. Grützmann R. Boriss H. Ammerpohl O. Lüttges J. Kalthoff H. Schackert H. K. et al. (2005). Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24 5079-5088. doi: 10.1038/sj.onc.1208696
50. Gupta R. K. Hué S. Schaller T. Verschoor E. Pillay D. and Towers G. J. (2009a). Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 5:e1000443. doi: 10.1371/journal.ppat.1000443
51. Gupta R. K. Mlcochova P. Pelchen-Matthews A. Petit S. J. Mattiuzzo G. Pillay D. et al. (2009b). Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U.S.A. 106 20889-20894. doi: 10.1073/pnas.0907075106
52. Gustin J. K. Douglas J. L. Bai Y. and Moses A. V. (2012). Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine serine or threonine residues within the BST-2 cytoplasmic domain. J. Biol. Chem. 287 14837-14850. doi: 10.1074/jbc.M112.349928
53. Guzzo C. Jung M. Graveline A. Banfield B. W. and Gee K. (2012). IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN. Sci. Rep. 2 974. doi: 10.1038/srep00974
54. Habermann A. Krijnse-Locker J. Oberwinkler H. Eckhardt M. Homann S. Andrew A. et al. (2010). CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J. Virol. 84 4646-4658. doi: 10.1128/JVI.02421-09
55. Hauser H. Lopez L. A. Yang S. J. Oldenburg J. E. Exline C. M. Guatelli J. C. et al. (2010). HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7 51. doi: 10.1186/1742-4690-7-51
56. Hegde R. S. Mastrianni J. A. Scott M. R. DeFea K. A. Tremblay P. Torchia M. et al. (1998). A transmembrane form of the prion protein in neurodegenerative disease. Science 279 827-834. doi: 10.1126/science.279.5352.827
57. Hegde R. S. Tremblay P. Groth D. DeArmond S. J. Prusiner S. B. and Lingappa V. R. (1999). Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402 822-826. doi: 10.1038/45574
58. Hitt A. L. Hartwig J. H. and Luna E. J. (1994a). Ponticulin is the major high affinity link between the plasma membrane and the cortical actin network in Dictyostelium. J. Cell Biol. 126 1433-1444. doi: 10.1083/jcb.126.6.1433
59. Hitt A. L. Lu T. H. and Luna E. J. (1994b). Ponticulin is an atypical membrane protein. J. Cell Biol. 126 1421-1431. doi: 10.1083/jcb.126.6.1421
60. Homann S. Smith D. Little S. Richman D. and Guatelli J. (2011). Upregulation of BST-2/Tetherin by HIV infection in vivo. J. Virol. 85 10659-10668. doi: 10.1128/JVI.05524-11
61. Ilinskaya A. Derse D. Hill S. Princler G. and Heidecker G. (2013). Cell-cell transmission allows human T-lymphotropic virus 1 to circumvent tetherin restriction. Virology 436 201-209. doi: 10.1016/j.virol.2012.11.012
62. Ishikawa J. Kaisho T. Tomizawa H. Lee B. O. Kobune Y. Inazawa J. et al. (1995). Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene BST2 that may be involved in pre-B-cell growth. Genomics 26 527-534. doi: 10.1016/0888-7543(95)80171-H
63. Iwabu Y. Fujita H. Kinomoto M. Kaneko K. Ishizaka Y. Tanaka Y. et al. (2009). HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 284 35060-35072. doi: 10.1074/jbc.M109.058305
64. Jakobsen M. R. Bak R. O. Andersen A. Berg R. K. Jensen S. B. Tengchuan J. et al. (2013). IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc. Natl. Acad. Sci. U.S.A. 110 E4571-E4580. doi: 10.1073/pnas.1311669110
65. Janvier K. Pelchen-Matthews A. Renaud J.-B. Caillet M. Marsh M. and Berlioz-Torrent C. (2011). The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog. 7:e1001265. doi: 10.1371/journal.ppat.1001265
66. Jeffery C. J. (2003). Moonlighting proteins: old proteins learning new tricks. Trends Genet. 19 415-417. doi: 10.1016/S0168-9525(03)00167-7
67. Jia B. Serra-Moreno R. Neidermyer W. Rahmberg A. Mackey J. Fofana I. B. et al. (2009). Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5:e1000429. doi: 10.1371/journal.ppat.1000429
68. Jolly C. Booth N. J. and Neil S. J. D. (2010). Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J. Virol. 84 12185-12199. doi: 10.1128/JVI.01447-10
69. Jones P. H. Maric M. Madison M. N. Maury W. Roller R. J. and Okeoma C. M. (2013). BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Virology 438 37-49. doi: 10.1016/j.virol.2013.01.010
70. Jouvenet N. Neil S. J. D. Zhadina M. Zang T. Kratovac Z. Lee Y. et al. (2009). Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83 1837-1844. doi: 10.1128/JVI.02211-08
71. Kauffman S. A. (1969). Metabolic stability and epigenesis in randomly constructed genetic nets. J. Theor. Biol. 22 437-467. doi: 10.1016/0022-5193(69)90015-0
72. Kawai S. Yoshimura Y. Iida S.-I. Kinoshita Y. Koishihara Y. Ozaki S. et al. (2006). Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol. Rep. 15 361-367.
73. Kleiger G. Grothe R. Mallick P. and Eisenberg D. (2002). GXXXG and AXXXA: common alpha-helical interaction motifs in proteins particularly in extremophiles. Biochemistry 41 5990-5997. doi: 10.1021/bi0200763
74. Klein F. Mouquet H. Dosenovic P. Scheid J. F. Scharf L. and Nussenzweig M. C. (2013). Antibodies in HIV-1 vaccine development and therapy. Science 341 1199-1204. doi: 10.1126/science.1241144
75. Kluge S. F. Sauter D. Vogl M. Peeters M. Li Y. Bibollet-Ruche F. et al. (2013). The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function. Retrovirology 10 32. doi: 10.1186/1742-4690-10-32
76. Kobayashi T. Ode H. Yoshida T. Sato K. Gee P. Yamamoto S. P. et al. (2011). Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J. Virol. 85 932-945. doi: 10.1128/JVI.01668-10
77. Kong W.-S. Irie T. Yoshida A. Kawabata R. Kadoi T. and Sakaguchi T. (2012). Inhibition of virus-like particle release of Sendai virus and Nipah virus but not that of mumps virus by tetherin/CD317/BST-2. Hiroshima J. Med. Sci. 61 59-67.
78. Köster B. and Strand M. (1994). Schistosoma mansoni: Sm23 is a transmembrane protein that also contains a glycosylphosphatidylinositol anchor. Arch. Biochem. Biophys. 310 108-117. doi: 10.1006/abbi.1994.1146
79. Kueck T. and Neil S. J. D. (2012). A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog. 8:e1002609. doi: 10.1371/journal.ppat.1002609
80. Kühl A. Banning C. Marzi A. Votteler J. Steffen I. Bertram S. et al. (2011). The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 204(Suppl. 3) S850-S860. doi: 10.1093/infdis/jir378
81. Kuhl B. D. Sloan R. D. Donahue D. A. Bar-Magen T. Liang C. and Wainberg M. A. (2010). Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 7 115. doi: 10.1186/1742-4690-7-115
82. Kupzig S. Korolchuk V. Rollason R. Sugden A. Wilde A. and Banting G. (2003). Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4 694-709. doi: 10.1034/j.1600-0854.2003.00129.x
83. Lanford R. E. Guerra B. Lee H. Chavez D. Brasky K. M. and Bigger C. B. (2006). Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 43 961-972. doi: 10.1002/hep.21167
84. Lehmann M. Rocha S. Mangeat B. Blanchet F. Uji-I H. Hofkens J. et al. (2011). Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction. PLoS Pathog. 7:e1002456. doi: 10.1371/journal.ppat.1002456
85. Le Tortorec A. and Neil S. J. D. (2009). Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83 11966-11978. doi: 10.1128/JVI.01515-09
86. Leyva-Grado V. H. Hai R. Fernandes F. Belicha-Villanueva A. Carter C. and Yondola M. A. (2013). Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo. J. Mol. Biol. doi: 10.1016/j.jmb.2013.12.023
87. Li X. Kaloyanova D. van Eijk M. Eerland R. van der Goot G. Oorschot V. et al. (2007). Involvement of a Golgi-resident GPI-anchored protein in maintenance of the Golgi structure. Mol. Biol. Cell 18 1261-1271. doi: 10.1091/mbc.E06-03-0236
88. Liberatore R. A. and Bieniasz P. D. (2011). Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 108 18097-18101. doi: 10.1073/pnas.1113694108
89. Lim E. S. and Emerman M. (2009). Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST-2. J. Virol. 83 11673-11681. doi: 10.1128/JVI.00569-09
90. Lim E. S. Malik H. S. and Emerman M. (2010). Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J. Virol. 84 7124-7134. doi: 10.1128/JVI.00468-10
91. Lindwasser O. W. Smith W. J. Chaudhuri R. Yang P. Hurley J. H. and Bonifacino J. S. (2008). A diacidic motif in human immunodeficiency virus type 1 Nef is a novel determinant of binding to AP-2. J. Virol. 82 1166-1174. doi: 10.1128/JVI.01874-07
92. Liu M.-Q. Zhou D.-J. Wang X. Zhou W. Ye L. Li J.-L. et al. (2012). IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS ONE 7:e35902. doi: 10.1371/journal.pone.0035902
93. Lopez L. A. Yang S. J. Hauser H. Exline C. M. Haworth K. G. Oldenburg J. et al. (2010). Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 84 7243-7255. doi: 10.1128/JVI.02636-09
94. Mangeat B. Cavagliotti L. Lehmann M. Gers-Huber G. Kaur I. Thomas Y. et al. (2012). Influenza virus partially counteracts restriction imposed by tetherin/BST-2. J. Biol. Chem. 287 22015-22029. doi: 10.1074/jbc.M111.319996
95. Mangeat B. Gers-Huber G. Lehmann M. Zufferey M. Luban J. and Piguet V. (2009). HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5:e1000574. doi: 10.1371/journal.ppat.1000574
96. Mansouri M. Viswanathan K. Douglas J. L. Hines J. Gustin J. Moses A. V. et al. (2009). Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J. Virol. 83 9672-9681. doi: 10.1128/JVI.00597-09
97. Masuyama N. Kuronita T. Tanaka R. Muto T. Hirota Y. Takigawa A. et al. (2009). HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J. Biol. Chem. 284 15927-15941. doi: 10.1074/jbc.M109.005124
98. Matsuda A. Suzuki Y. Honda G. Muramatsu S. Matsuzaki O. Nagano Y. et al. (2003). Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 22 3307-3318. doi: 10.1038/sj.onc.1206406
99. McNatt M. W. Zang T. and Bieniasz P. D. (2013). Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog. 9:e1003299. doi: 10.1371/journal.ppat.1003299
100. McNatt M. W. Zang T. Hatziioannou T. Bartlett M. Fofana I. B. Johnson W. E. et al. (2009). Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5:e1000300. doi: 10.1371/journal.ppat.1000300
101. Mitchell R. S. Katsura C. Skasko M. A. Fitzpatrick K. Lau D. Ruiz A. et al. (2009). Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5:e1000450. doi: 10.1371/journal.ppat.1000450
102. Morrison J. H. Guevara R. B. Marcano A. Saenz D. T. Fadel H. J. Rogstad D. K. et al. (2014). FIV envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation. J. Virol. 88 3255-3272. doi: 10.1128/JVI.03814-13
103. Mous K. Jennes W. Camara M. Seydi M. Daneau G. Mboup S. et al. (2012). Expression analysis of LEDGF/p75 APOBEC3G TRIM5alpha and tetherin in a Senegalese cohort of HIV-1-exposed seronegative individuals. PLoS ONE 7:e33934. doi: 10.1371/journal.pone.0033934
104. Neil S. J. D. Sandrin V. Sundquist W. I. and Bieniasz P. D. (2007). An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2 193-203. doi: 10.1016/j.chom.2007.08.001
105. Neil S. J. D. Zang T. and Bieniasz P. D. (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 425-430. doi: 10.1038/nature06553
106. Ng B. G. Hackmann K. Jones M. A. Eroshkin A. M. He P. Wiliams R. et al. (2012). Mutations in the glycosylphosphatidylinositol gene PIGL cause CHIME syndrome. Am. J. Hum. Genet. 90 685-688. doi: 10.1016/j.ajhg.2012.02.010
107. Nguyen D. H. and Hildreth J. E. (2000). Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J. Virol. 74 3264-3272. doi: 10.1128/JVI.74.7.3264-3272.2000
108. Nishikawa Y. Tragoolpua K. Makala L. Xuan X. and Nagasawa H. (2002). Neospora caninum NcSRS2 is a transmembrane protein that contains a glycosylphosphatidylinositol anchor in insect cells. Vet. Parasitol. 109 191-201. doi: 10.1016/S0304-4017(02)00256-X
109. Ohtomo T. Sugamata Y. Ozaki Y. Ono K. Yoshimura Y. Kawai S. et al. (1999). Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258 583-591. doi: 10.1006/bbrc.1999.0683
110. Pais-Correia A.-M. Sachse M. Guadagnini S. Robbiati V. Lasserre R. Gessain A. et al. (2010). Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat. Med. 16 83-89. doi: 10.1038/nm.2065
111. Pan X.-B. Qu X.-W. Jiang D. Zhao X.-L. Han J.-C. and Wei L. (2013). BST2/tetherin inhibits hepatitis C virus production in human hepatoma cells. Antiviral Res. 98 54-60. doi: 10.1016/j.antiviral.2013.01.009
112. Pardieu C. Vigan R. Wilson S. J. Calvi A. Zang T. Bieniasz P. et al. (2010). The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog. 6:e1000843. doi: 10.1371/journal.ppat.1000843
113. Pennisi E. (2012). Genomics. ENCODE project writes eulogy for junk DNA. Science 337 1159 1161. doi: 10.1126/science.337.6099.1159
114. Perez-Caballero D. Zang T. Ebrahimi A. McNatt M. W. Gregory D. A. Johnson M. C. et al. (2009). Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139 499-511. doi: 10.1016/j.cell.2009.08.039
115. Petit S. J. Blondeau C. and Towers G. J. (2011). Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin. J. Gen. Virol. 92 2937-2948. doi: 10.1099/vir.0.035931-0
116. Petris G. Casini A. Sasset L. Cesaratto F. Bestagno M. Cereseto A. et al. (2014). CD4 and BST-2/tetherin proteins retro-translocate from endoplasmic reticulum to cytosol as partially folded and multimeric molecules. J. Biol. Chem. 289 1-12. doi: 10.1074/jbc.M113.512368
117. Pham T. N. Lukhele S. Hajjar F. Routy J.-P. and Cohen E. A. (2014). HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell Lysis through down-modulation of CD4 and BST2. Retrovirology 11 15. doi: 10.1186/1742-4690-11-15
118. Pickering S. Hué S. Kim E.-Y. Reddy S. Wolinsky S. M. and Neil S. J. D. (2014). Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog. 10:e1003895. doi: 10.1371/journal.ppat.1003895
119. Plantier J.-C. Leoz M. Dickerson J. E. De Oliveira F. Cordonnier F. Lemée V. et al. (2009). A new human immunodeficiency virus derived from gorillas. Nat. Med. 15 871-872. doi: 10.1038/nm.2016
120. Radoshitzky S. R. Dong L. Chi X. Clester J. C. Retterer C. Spurgers K. et al. (2010). Infectious Lassa virus but not filoviruses is restricted by BST-2/tetherin. J. Virol. 84 10569-10580. doi: 10.1128/JVI.00103-10
121. Rahmberg A. R. Neidermyer W. J. Jr. Breed M. W. Alvarez X. Midkiff C. C. Piatak M. et al. (2013). Tetherin upregulation in simian immunodeficiency virus-infected macaques. J. Virol. 87 13917-13921. doi: 10.1128/JVI.01757-13
122. Rollason R. Dunstan K. Billcliff P. G. Bishop P. Gleeson P. Wise H. et al. (2013). Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation. PLoS ONE 8:e75680. doi: 10.1371/journal.pone.0075680
123. Rollason R. Korolchuk V. Hamilton C. Schu P. and Banting G. (2007). Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J. Cell Sci. 120 3850-3858. doi: 10.1242/jcs.003343
124. Rong L. Zhang J. Lu J. Pan Q. Lorgeoux R.-P. Aloysius C. et al. (2009). The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 83 7536-7546. doi: 10.1128/JVI.00620-09
125. Sakuma T. Noda T. Urata S. Kawaoka Y. and Yasuda J. (2009). Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83 2382-2385. doi: 10.1128/JVI.01607-08
126. Sarojini S. Theofanis T. and Reiss C. S. (2011). Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. DNA Cell Biol. 30 965-974. doi: 10.1089/dna.2011.1384
127. Sato K. Misawa N. Fukuhara M. Iwami S. An D. S. Ito M. et al. (2012). Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J. Virol. 86 5000-5013. doi: 10.1128/JVI.07062-11
128. Sauter D. Hotter D. Engelhart S. Giehler F. Kieser A. Kubisch C. et al. (2013). A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release. Retrovirology 10 85. doi: 10.1186/1742-4690-10-85
129. Sauter D. Hue S. Petit S. J. Plantier J.-C. Towers G. J. Kirchhoff F. et al. (2011a). HIV-1 Group P is unable to antagonize human tetherin by Vpu Env or Nef. Retrovirology 8 103. doi: 10.1186/1742-4690-8-103
130. Sauter D. Vogl M. and Kirchhoff F. (2011b). Ancient origin of a deletion in human BST2/Tetherin that confers protection against viral zoonoses. Hum. Mutat. 32 1243-1245. doi: 10.1002/humu.21571
131. Sauter D. Schindler M. Specht A. Landford W. N. Münch J. Kim K.-A. et al. (2009). Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6 409-421. doi: 10.1016/j.chom.2009.10.004
132. Sauter D. Specht A. and Kirchhoff F. (2010). Tetherin: holding on and letting go. Cell 141 392-398. doi: 10.1016/j.cell.2010.04.022
133. Sauter D. Unterweger D. Vogl M. Usmani S. M. Heigele A. Kluge S. F. et al. (2012). Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog. 8:e1003093. doi: 10.1371/journal.ppat.1003093
134. Sayeed A. Luciani-Torres G. Meng Z. Bennington J. L. Moore D. H. and Dairkee S. H. (2013). Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells. PLoS ONE 8:e67191. doi: 10.1371/journal.pone.0067191
135. Schindler M. Rajan D. Banning C. Wimmer P. Koppensteiner H. Iwanski A. et al. (2010). Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages but not in ex vivo human lymphoid tissue. Retrovirology 7 1. doi: 10.1186/1742-4690-7-1
136. Schmidt S. Fritz J. V. Bitzegeio J. Fackler O. T. and Keppler O. T. (2011). HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. mBio 2:e00036-e00011. doi: 10.1128/mBio.00036-11
137. Schmökel J. Sauter D. Schindler M. Leendertz F. H. Bailes E. Dazza M.-C. et al. (2011). The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses. J. Virol. 85 742-752. doi: 10.1128/JVI.02087-10
138. Schneider D. and Engelman D. M. (2004). Motifs of two small residues can assist but are not sufficient to mediate transmembrane helix interactions. J. Mol. Biol. 343 799-804. doi: 10.1016/j.jmb.2004.08.083
139. Schubert H. L. Zhai Q. Sandrin V. Eckert D. M. Garcia-Maya M. Saul L. et al. (2010). Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc. Natl. Acad. Sci. U.S.A. 107 17951-17956. doi: 10.1073/pnas.1008206107
140. Serra-Moreno R. Jia B. Breed M. Alvarez X. and Evans D. T. (2011). Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe 9 46-57. doi: 10.1016/j.chom.2010.12.005
141. Serra-Moreno R. Zimmermann K. Stern L. J. and Evans D. T. (2013). Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin and on clathrin-mediated endocytosis. PLoS Pathog. 9:e1003487. doi: 10.1371/journal.ppat.1003487
142. Sharp P. M. and Hahn B. H. (2011). Origins of HIV and the AIDS pandemic. Cold Spring Harb. Perspect. Med. 1:a006841. doi: 10.1101/cshperspect.a006841
143. Sheehy A. M. Gaddis N. C. Choi J. D. and Malim M. H. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 646-650. doi: 10.1038/nature00939
144. Skasko M. Tokarev A. Chen C.-C. Fischer W. B. Pillai S. K. and Guatelli J. (2011). BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology 411 65-77. doi: 10.1016/j.virol.2010.12.038
145. Stewart R. S. Drisaldi B. and Harris D. A. (2001). A transmembrane form of the prion protein contains an uncleaved signal peptide and is retained in the endoplasmic Reticulum. Mol. Biol. Cell 12 881-889. doi: 10.1091/mbc.12.4.881
146. Stremlau M. Owens C. M. Perron M. J. Kiessling M. Autissier P. and Sodroski J. (2004). The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 848-853. doi: 10.1038/nature02343
147. Swiecki M. Scheaffer S. M. Allaire M. Fremont D. H. Colonna M. and Brett T. J. (2011). Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J. Biol. Chem. 286 2987-2997. doi: 10.1074/jbc.M110.190538
148. Swiecki M. Wang Y. Gilfillan S. Lenschow D. J. and Colonna M. (2012). Cutting edge: paradoxical roles of BST2/tetherin in promoting type I IFN response and viral infection. J. Immunol. 188 2488-2492. doi: 10.4049/jimmunol.1103145
149. Tavano B. Galao R. P. Graham D. R. Neil S. J. D. Aquino V. N. Fuchs D. et al. (2013). Ig-like transcript 7 but not bone marrow stromal cell antigen 2 (also known as HM1.24 tetherin or CD317) modulates plasmacytoid dendritic cell function in primary human blood leukocytes. J. Immunol. 190 2622-2630. doi: 10.4049/jimmunol.1202391
150. Tervo H.-M. Homann S. Ambiel I. Fritz J. V. Fackler O. T. and Keppler O. T. (2011). β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology 8 9. doi: 10.1186/1742-4690-8-9
151. Tokarev A. A. Munguia J. and Guatelli J. C. (2011). Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J. Virol. 85 51-63. doi: 10.1128/JVI.01795-10
152. Tokarev A. Suarez M. Kwan W. Fitzpatrick K. Singh R. and Guatelli J. (2013). Stimulation of NF-kB activity by the HIV restriction factor BST2. J. Virol. 87 2046-2057. doi: 10.1128/JVI.02272-12
153. Van Damme N. Goff D. Katsura C. Jorgenson R. L. Mitchell R. Johnson M. C. et al. (2008). The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3 245-252. doi: 10.1016/j.chom.2008.03.001
154. Venkatesh S. and Bieniasz P. D. (2013). Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog. 9:e1003483. doi: 10.1371/journal.ppat.1003483
155. Vessière A. Rousset D. Kfutwah A. Leoz M. Depatureaux A. Simon F. et al. (2010). Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J. Acquir. Immune Defic. Syndr. 53 107-110. doi: 10.1097/QAI.0b013e3181b97ec1
156. Vidal-Laliena M. Romero X. March S. Requena V. Petriz J. and Engel P. (2005). Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell. Immunol. 236 6-16. doi: 10.1016/j.cellimm.2005.08.002
157. Vigan R. and Neil S. J. D. (2010). Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J. Virol. 84 12958-12970. doi: 10.1128/JVI.01699-10
158. Viswanathan K. Smith M. S. Malouli D. Mansouri M. Nelson J. A. and Früh K. (2011). BST2/Tetherin enhances entry of human cytomegalovirus. PLoS Pathog. 7:e1002332. doi: 10.1371/journal.ppat.1002332
159. Walter-Yohrling J. Cao X. Callahan M. Weber W. Morgenbesser S. Madden S. L. et al. (2003). Identification of genes expressed in malignant cells that promote invasion. Cancer Res. 63 8939-8947.
160. Wang S.-M. Huang K.-J. and Wang C.-T. (2014). BST2/CD317 counteracts human coronavirus 229E productive infection by tethering virions at the cell surface. Virology 449 287-296. doi: 10.1016/j.virol.2013.11.030
161. Wang Y. Wang X. Li J. Zhou Y. and Ho W. (2013). RIG-I activation inhibits HIV replication in macrophages. J. Leukoc. Biol. 94 337-341. doi: 10.1189/jlb.0313158
162. Weidner J. M. Jiang D. Pan X.-B. Chang J. Block T. M. and Guo J.-T. (2010). Interferon-induced cell membrane proteins IFITM3 and tetherin inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84 12646-12657. doi: 10.1128/JVI.01328-10
163. Wong S. K. Connole M. Sullivan J. S. Choe H. Carville A. and Farzan M. (2009). A New World primate deficient in tetherin-mediated restriction of human immunodeficiency virus type 1. J. Virol. 83 8771-8780. doi: 10.1128/JVI.00112-09
164. Yadav S. S. Wilson S. J. and Bieniasz P. D. (2012). A facile quantitative assay for viral particle genesis reveals cooperativity in virion assembly and saturation of an antiviral protein. Virology 429 155-162. doi: 10.1016/j.virol.2012.04.008
165. Yang H. Wang J. Jia X. McNatt M. W. Zang T. Pan B. et al. (2010a). Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc. Natl. Acad. Sci. U.S.A. 107 18428-18432. doi: 10.1073/pnas.1011485107
166. Yang S. J. Lopez L. A. Hauser H. Exline C. M. Haworth K. G. and Cannon P. M. (2010b). Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7 13. doi: 10.1186/1742-4690-7-13
167. Ye H. Arron J. R. Lamothe B. Cirilli M. Kobayashi T. Shevde N. K. et al. (2002). Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418 443-447. doi: 10.1038/nature00888
168. Ye L. Wang X. Li J. Liu J. Ramirez S. H. Wu J. et al. (2012). Tetherin has negligible activity in restricting hepatitis C virus in hepatocytes. Innate Immun. 18 398-405. doi: 10.1177/1753425911412984
169. Yin X. Hu Z. Gu Q. Wu X. Zheng Y.-H. Wei P. et al. (2014). Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein. J. Virol. 88 1259-1270. doi: 10.1128/JVI.03148-13
170. Yondola M. A. Fernandes F. Belicha-Villanueva A. Uccelini M. Gao Q. Carter C. et al. (2011). Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J. Virol. 85 2480-2491. doi: 10.1128/JVI.02188-10
171. Zhang F. Landford W. N. Ng M. McNatt M. W. Bieniasz P. D. and Hatziioannou T. (2011). SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathog. 7:e1002039. doi: 10.1371/journal.ppat.1002039
172. Zhang F. Wilson S. J. Landford W. C. Virgen B. Gregory D. Johnson M. C. et al. (2009). Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6 54-67. doi: 10.1016/j.chom.2009.05.008
173. Zhou Y. Wang X. Liu M. Hu Q. Song L. Ye L. et al. (2010). A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages. Immunology 131 40-49. doi: 10.1111/j.1365-2567.2010.03270.x